ESPR — Esperion Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $369.33m
- $548.68m
- $116.33m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 148 | 228 | 78.4 | 75.5 | 116 |
Cost of Revenue | |||||
Gross Profit | — | 225 | 64.2 | 48.5 | 73.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 241 | 349 | 305 | 255 | 272 |
Operating Profit | -93.1 | -121 | -227 | -180 | -156 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -97.2 | -144 | -269 | -234 | -209 |
Net Income After Taxes | -97.2 | -144 | -269 | -234 | -209 |
Net Income Before Extraordinary Items | |||||
Net Income | -97.2 | -144 | -269 | -234 | -209 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -97.2 | -144 | -269 | -234 | -209 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.59 | -5.22 | -8.85 | -3.52 | -2.03 |